| 764468 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
780 ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.780 |
Harrabi Ons, Chen Amy, Sangalang Emma, Fontaine Danielle, Li Min, Pons Jaume, Wan Hong, Sim Janet, Kuo Tracy |
| 764467 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
779 Inhibiting type-I interferon signaling promotes memory T-cell formation following immunization with Listeria anti-cancer vaccines |
2021-11-01 |
10.1136/jitc-2021-sitc2021.779 |
Morrow Zachary, Sauer John-Demian |
| 764466 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
778 Modulating tumor microenvironment with arginase-1 specific T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.778 |
Martinenaite Evelina, Jørgensen Mia Aaboe, Johansson Mortensen Rasmus Erik, Ahmad Shamaila Munir, Weis-Banke Stine Emilie, Holmström Morten Orebo, Pedersen Ayako Wakatsuki, Met Özcan, Svane Inge, Andersen Mads Hald |
| 764465 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
777 Personalized DNA vaccine in combination with plasmid encoded IL-12 for the treatment of a patient with anaplastic astrocytoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.777 |
Johanns Tanner, Perales-Puchalt Alfredo, Rochestie Sarah, Cooch Neil, Peters Joann, Dunn Gavin, Sardesai Niranjan |
| 764464 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
631 Deep, durable response to PD-1 inhibitor monotherapy in microsatellite-stable, tumor mutational burden-high colorectal cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.631 |
Schellenberg Samuel, Kim Leeseul, Chae Young Kwang |
| 764463 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
630 Oncologists' perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US |
2021-11-01 |
10.1136/jitc-2021-sitc2021.630 |
Grivas Petros, Veeranki Phani, Chiu Kevin, Pawar Vivek, Chang Jane, Bharmal Murtuza |
| 764462 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
625 COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.625 |
Hwang Joyce, Dzimitrowicz Hannah, Shah Riddhishkumar, Ashcraft Kathleen, George Daniel, Salama April, Zhang Tian |
| 764461 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
624 Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses |
2021-11-01 |
10.1136/jitc-2021-sitc2021.624 |
Shi Leilei, Fedoriw Andrew, O’Brien Shane, Smitheman Kimberly, Wang Yunfei, Hou Jiakai, Sherk Christian, Rajapurkar Satyajit, Laraio Jenny, Williams Leila, Xu Chunyu, Han Guangchun, Feng Qin, Bedford Mark, Wang Linghua, Barbash Olena, Kruger Ryan, Hwu Patrick, Mohammad Helai, Peng Weiyi |
| 764460 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
622 Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege |
2021-11-01 |
10.1136/jitc-2021-sitc2021.622 |
Jayaprakash Priyamvada, Rice Meghan, Bhanu Krithikaa Rajkumar, Morrow Brittany, Marszalek Joseph, Gay Jason, Vellano Christopher, Cowen Benjamin, Welsch Dean, Curran Michael |
| 764459 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
621 NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.621 |
Horowitz Amir, Daza Jorge, Alice Wang Y, Ranti Daniel, Salome Berengere, Merritt Elliot, Cavallo-Fleming Julie-Ann, Hegewisch-Solloa Everado, Mace Emily, Farkas Adam, Shroff Sanjana, Tran Michelle, Qi Jingjing, Patel Manishkumar, Geanon Daniel, Kelly Geoffrey, Real Ronaldo de, Lee Brian, Kim-Schulze Seunghee, Thin Tin Htwe, Garcia-Barros Monica, Beaumont Kristin, Wang Ying-Chih, Wang Li, LaRoche Dominic, Lee Yong, Sebra Robert, Brody Rachel, Mehrazin Reza, Zhu Jun, Tocheva Anna, Hopkins Benjamin, Wiklund Peter, Galsky Matthew, Bhardwaj Nina, Sfakianos John |
